First clinical study started and long-term financing secured
Significant events during the second quarter 2021
Applied Ventures invested a furtherUSD 0.5 million through the exercise of warrants issued in connection with the directed share issue in Q1 2021.Nanexa receivedSEK 4.3 million through the issue and the number of shares and votes in the company increased by 480,879 to 25,347,813 shares and votes.Nanexa started its first clinical trial at the end ofApril 2021 . It is a phase I study in the NEX-18 project to study pharmacokinetics, safety and tolerability. The first patients were treated at the end ofMay 2021 .Nanexa received approval inChina inMay 2021 for its basic patent, which covers the manufacturing method, products derived from it, and the use of PharmaShell®-coated drugs.- At Nanexa’s Annual General Meeting on
May 24 , it was decided, among other things, to elect Eva Nilsagård andBirgit Stattin Norinder as new Board members, on authorizations for the Board to decide on rights issue and directed issue, and to establish a warrant based incentive program for employees. A total of 380,000 warrants were thereafter subscribed for, corresponding to a maximum dilution of 1.5%. - In
May 2021 ,Nanexa filed a complaint of patent infringement in theUnited States District Court of Delaware filed a patent infringement lawsuit againstVitrivax, Inc. Nanexa decided inJune 2021 to carry out a fully guaranteed rights issue of approximatelySEK 127 million . The subscription period ran from 17 June to1 July 2021 .Nanexa received approval inSouth Korea inJune 2021 for its basic patent on PharmaShell®-coated drugs.
Significant events after the end of the period
- The
European Patent Office (EPO) communicated its intention to grant a European patent forNanexa 's PharmaShell® technology. - The rights issue of
SEK 127 million decided in June was completed and registered inJuly 2021 .
Summary of the reporting period 1 April -
- Turnover amounted to: TSEK 342 (97)
- Operating profit (EBIT) amounted to: TSEK -8,296 (-6,430)
- Profit after tax amounted to: TSEK -8,339 (-6,494)
- Earnings per share amounted to:
SEK -0.33 (-0.31) - Cash flow for the period amounted to: TSEK -6,253 (-9,961)
- Cash and cash equivalents at end of period: TSEK 28,596 (34,089)
Summary of the reporting period 1 January -
- Turnover amounted to: TSEK 878 (1,289)
- Operating profit (EBIT) amounted to: TSEK -14,919 (-9,899)
- Profit after tax amounted to: TSEK -15,008 (-10,020)
- Earnings per share amounted to:
SEK -0.64 (-0.54) - Cash flow for the period amounted to: TSEK 15,905 (22,711)
- Cash and cash equivalents at end of period: TSEK 28,596 (34,089)
Figures in brackets refer to the corresponding period in the previous year.
© Modular Finance, source